PubMed:24798767 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/24798767","sourcedb":"PubMed","sourceid":"24798767","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/24798767","text":"Immunologic effect of zinc supplementation in HIV-infected children receiving highly active antiretroviral therapy: a randomized, double-blind, placebo-controlled trial.\nBACKGROUND: We conducted this study to assess the immunologic effect of daily 20 mg zinc supplementation for 24 weeks in HIV-infected children older than 6 months receiving highly active antiretroviral therapy (ART).\nMETHODS: Fifty-two HIV-infected children older than 6 months in whom ART was initiated were randomized to receive either 20 mg of zinc or placebo for a period of 24 weeks. Children underwent clinical examination, anthropometry, and laboratory evaluations: CD4% and count, viral load, and serum zinc level at baseline, 12 weeks, and 24 weeks. The primary outcome evaluated was CD4% value at the end of 12 and 24 weeks of study intervention in the enrolled children.\nRESULTS: Of 52 children enrolled, 49 completed the study. The median CD4% value rose from 10% to 23% at 12 weeks and to 24.5% at 24 weeks in the zinc group, whereas in the placebo group, the value rose from 11% to 20% at 12 weeks and to 22% at 24 weeks (P = 0.188 for comparison between the zinc and the placebo group at 12 wk and P = 0.3 for comparison at 24 wk). The median (interquartile range) log reductions in the viral load at 12 weeks in the 2 arms were similar at 12 (P = 0.84) and 24 weeks (P = 0.43).\nCONCLUSIONS: Supplementation of 20 mg zinc daily for 24 weeks did not have any statistically significant effect on the increase in CD4%, decrease in viral load, anthropometric indices, and morbidity profile in HIV-infected children started on ART.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_24798767_2_0","span":{"begin":357,"end":379},"obj":"expanded"},{"id":"SS2_24798767_2_0","span":{"begin":381,"end":384},"obj":"abbr"}],"relations":[{"id":"AE1_24798767_2_0","pred":"abbreviatedTo","subj":"SS1_24798767_2_0","obj":"SS2_24798767_2_0"}],"attributes":[{"subj":"SS1_24798767_2_0","pred":"source","obj":"Allie"},{"subj":"SS2_24798767_2_0","pred":"source","obj":"Allie"}]},{"project":"wangzhuo19_800","denotations":[{"id":"T1","span":{"begin":254,"end":258},"obj":"CI"},{"id":"T2","span":{"begin":22,"end":26},"obj":"CI"},{"id":"T3","span":{"begin":517,"end":521},"obj":"CI"},{"id":"T4","span":{"begin":997,"end":1001},"obj":"CI"},{"id":"T5","span":{"begin":1143,"end":1147},"obj":"CI"},{"id":"T6","span":{"begin":1402,"end":1406},"obj":"CI"},{"id":"T7","span":{"begin":46,"end":67},"obj":"DP"},{"id":"T8","span":{"begin":291,"end":312},"obj":"DP"},{"id":"T9","span":{"begin":406,"end":427},"obj":"DP"},{"id":"T10","span":{"begin":1574,"end":1595},"obj":"DP"}],"attributes":[{"subj":"T1","pred":"source","obj":"wangzhuo19_800"},{"subj":"T2","pred":"source","obj":"wangzhuo19_800"},{"subj":"T3","pred":"source","obj":"wangzhuo19_800"},{"subj":"T4","pred":"source","obj":"wangzhuo19_800"},{"subj":"T5","pred":"source","obj":"wangzhuo19_800"},{"subj":"T6","pred":"source","obj":"wangzhuo19_800"},{"subj":"T7","pred":"source","obj":"wangzhuo19_800"},{"subj":"T8","pred":"source","obj":"wangzhuo19_800"},{"subj":"T9","pred":"source","obj":"wangzhuo19_800"},{"subj":"T10","pred":"source","obj":"wangzhuo19_800"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#e3ec93","default":true},{"id":"wangzhuo19_800","color":"#da93ec"}]}]}}